Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 4/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873008 | 0.87 | F10 (0.49) | F10TP53ALDH1A1UBE2MDCUN1D1 | |
| SCHEMBL2737094 | 0.81 | F10 (0.63) | F10MAPK1TP53SMN1; SMN2 | |
| SCHEMBL221193 | 0.80 | F10 (0.69) | F10MAPK1SMN1; SMN2 | |
| SCHEMBL219798 | 0.80 | F10 (1.00) | F10MAPK1SMN1; SMN2 | |
| SCHEMBL219860 | 0.79 | F10 (0.65) | F10MAPK1TP53SMN1; SMN2 | |
| SCHEMBL220475 | 0.79 | F10 (0.67) | F10MAPK1SMN1; SMN2 | |
| SCHEMBL222611 | 0.78 | F10 (0.66) | F10MAPK1SMN1; SMN2 | |
| SCHEMBL221417 | 0.78 | F10 (0.63) | F10MAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL221251 | 0.78 | F10 (0.63) | F10MAPK1SMN1; SMN2 | |
| SCHEMBL219872 | 0.76 | F10 (0.63) | F10MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088925-B2 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | claimed |
| US-8088925-B2 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |